Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of...
-
Upload
lesley-quinn -
Category
Documents
-
view
223 -
download
0
Transcript of Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of...
![Page 1: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/1.jpg)
Dyslipoproteinemia and Atherosclerosis
Daniel W. Stock MD
Founding Diplomate, American Board of Clinical Lipidology
Member, National Lipid Association and Midwest Lipid Association
Former Adjunct Clinical ProfessorIndiana University School of Medicine
![Page 2: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/2.jpg)
Disclosures
Speakers Bureau: Liposcience Inc.Lilly Pharmaceuticals Inc.Warner-Chilcott Inc.
![Page 3: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/3.jpg)
•Framingham showed ↑’ing risk with ↑’ing LDL and ↓’ing HDL cholesterol
CAD status
LDL-C HDL-C AMCE ∆
4S 2º 188 46 34%
LIPID 2º 150 36 34%
CARE 2º 139 39 22%
WOSCOPS 1º 193 44 31%
AFCAPS/TexCAPS 1º 150 36 37%
ASCOT-LLA 1º 131 50 36%
HPS 1º& 2º NA NA 17%
JUPITER 1º 108 49 44%
VA-HIT 2º 112 32 22%
![Page 4: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/4.jpg)
Lipid Analysis Shortcomings
• 50% of Framingham AMCE patients had LDL <130 mg/dl
• 75% of Framingham AMCE patients < 55 yo had LDL <130 mg/dl
• Majority of lipid trial patients did not benefit from therapy
• On-treatment lipids did not predict clinical outcome
• Forces the treatment of low-risk individuals in order to protect high-risk individuals
![Page 5: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/5.jpg)
Beta HCG level
5 50 500 5000 500,000
Num
ber
of p
atie
nts
![Page 6: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/6.jpg)
0
5
10
15
20
25
30
0 100 200 300 400 500
total cholesterol
nu
mb
er o
f pat
ien
ts
![Page 7: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/7.jpg)
LDL Cholesterol
Num
ber
of p
atie
nts
![Page 8: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/8.jpg)
“Lipids” and Atherosclerosis
• Atherosclerosis occurs because of abnormal lipoproteins and/or lipoprotein kinetics, not abnormal lipid levels.
“… all abnormalities in plasma lipid concentrations, or dyslipidemia, can be translated into dyslipoproteinemia.”
“… the shift of emphasis to lipoproteins offers distinct advantages in the recognition and management of such disorders.”
Fredrickson et al., NEJM 1967; 276: 148
![Page 9: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/9.jpg)
Total Cholesterol (+)
VLDL-C + LDL-C + HDL-C(+) (+) (-)
IDL LDL
+ + + + + + + + + + - - - + +
Association with CHD: Positive (+) or Negative (-)
![Page 10: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/10.jpg)
Lipoprotein Particles
NON-POLARLIPID CORE
Cholesterol EsterTriglyceride
POLAR SURFACE COAT
Phospholipid
Free cholesterol
Apolipoprotein
Apolipoprotein
Apolipoprotein
![Page 11: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/11.jpg)
At the same LDL cholesterol, with small versus large size LDL Particles
Up to 70%More Particles
Small LDL
Large LDL
CholesterolBalance
100 mg/dL 100 mg/dL
Otvos JD, et al. Am J Cardiol 2002;90(suppl):22i-29i
Among Individuals At The Same LDL-C Level, The Number of LDL Particles Vary
Cromwell WC, et al. J Clin Lipidology. 2007;1(6):583-592.
![Page 12: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/12.jpg)
At the same LDL cholesterol, with the same size LDL Particles (at any triglyceride level)
Up to 40%More Particles
Less Cholesterol Carried Per Particle
Normal Cholesterol Carried Per Particle
100 mg/dL 100 mg/dL
Otvos JD, et al. Am J Cardiol 2002;90(suppl):22i-29i
Among Individuals At The Same LDL-C Level, The Number of LDL Particles Vary
Cromwell WC, et al. J Clin Lipidology. 2007;1(6):583-592.
CholesterolBalance
![Page 13: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/13.jpg)
LDL-C often fails to reflect the number of LDL particles and the CHD risk they confer
The number of LDL particles (LDL-P™) varies widely among patients with similar LDL-C values. In this analysis, patients with an LDL-C between 95 mg/dL and 105 mg/dL have highly variable LDL particles, and thus variable CHD risk.
Otvos JD, Jayarajah E, Cromwell, WC. AJC 2002;90(8A):22i-29i
![Page 14: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/14.jpg)
LDL-C Often Fails to Reflect the Number of LDL Particles
• LDL particles can be large or small, and the amount of cholesterol contained within these particles varies widely.
Otvos JD, Jayarajah E, Cromwell, WC. AJC 2002;90(8A):22i-29i
![Page 15: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/15.jpg)
Enhanced Macrophage Uptake
– Modified / retained lipoproteins
Enhanced Macrophage Uptake
– Modified / retained lipoproteins
Particle Movement
– Gradient driven
Particle Movement
– Gradient driven
Oxidative Modification Oxidative Modification
Adhesion molecules MCP-1
Colony-stimulatingfactors
Tissue factorPAI-1
Endothelial cellsEndothelial cells
MonocyteMonocyte
Particle Retention
– Lipoprotein particle binding to proteoglycans
Particle Retention
– Lipoprotein particle binding to proteoglycans
Mildly modified LDL
Extensively modified LDL
Pathophysiology of AtherosclerosisPathophysiology of Atherosclerosis
“The rate of passive diffusion is increased when the circulating levels of LDL are elevated.”
1
Enhanced Endothelial Dysfunction
Enhanced Endothelial Dysfunction
1 Weissberg PL, Rudd JH. Textbook of Cardiovascular Medicine 2nd ed. 2002. p. 6.
![Page 16: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/16.jpg)
Od
ds
Rat
io p
er 1
-SD
In
crem
ent
of
on
-tri
al v
alu
e
1
1.1
1.2
1.3
LDL-C Non-HDL-C
ApoB LDL-P
p<0.001
Alternative Measures of LDL as Predictors of CHD Events in VA-HIT
Adjusted for treatment, age, hypertension,smoking, BMI, and diabetes
p=0.31
p=0.17p=0.25
Circulation 2006;113:1556-63
![Page 17: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/17.jpg)
Adjusted for treatment, age, hypertension,smoking, BMI, and diabetes
1
1.1
1.2
1.3
1.4
1.5
HDL-C ApoA-1 HDL-P
p<0.001
p=0.18
p=0.42
Od
ds
Rat
io p
er 1
-SD
Dec
rem
ent
of
on
-tri
al v
alu
e
Alternative Measures of HDL as Predictors of CHD Events in VA-HIT
Circulation 2006;113:1556-63
![Page 18: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/18.jpg)
0.74
0.76
0.78
0.80
0.82
0.84
0.86
0.88
0.90
0.92
0.94
0.96
0.98
1.00
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Years of Follow-up
Eve
nt-F
ree
Sur
viva
l
Low LDL-P & Low LDL-C(n=1,249)
High LDL-P & High LDL-C (n=1,251)
Fig. 2 Survival Curves for Framingham Subjects withConcordant LDL-C and LDL-P
![Page 19: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/19.jpg)
Fig. 2 Survival Curves for Framingham Subjects withDiscordant LDL-C and LDL-P
0.74
0.76
0.78
0.80
0.82
0.84
0.86
0.88
0.90
0.92
0.94
0.96
0.98
1.00
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Years of Follow-up
Eve
nt-F
ree
Sur
viva
l
Low LDL-CHigh LDL-P
(n=282)
High LDL-CLow LDL-P
(n=284)
![Page 20: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/20.jpg)
0.74
0.76
0.78
0.80
0.82
0.84
0.86
0.88
0.90
0.92
0.94
0.96
0.98
1.00
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Years of Follow-up
Eve
nt-F
ree
Sur
viva
l
Low LDL-CHigh LDL-P
(n=282)
High LDL-CLow LDL-P
(n=284)
Low LDL-P & Low LDL-C(n=1,249)
High LDL-P & High LDL-C (n=1,251)
Fig. 2 Survival Curves for Framingham Subjects withConcordant and Discordant LDL-C and LDL-P
![Page 21: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/21.jpg)
NMR LDL-P significantly better risk predictor than all lipid panel parameters
Framing. Offspring Study*†
Cardiovascular Health Study*
VA-HIT*†
PLAC-1*
Healthy Women Study*
MESA*†
NMR LDL-P significantly better risk predictor than all lipid panel parameters except TC/HDL-C
Women’s Health Study*†
LDL pattern not an independent predictor of risk after NMR LDL-P adjustment
Framing. Offspring Study*†
VA-HIT*†
Women’s Health Study*†
MESA*†
NMR LDL-P vs. Lipids
* Independent of sex, age, smoking status and BP† Superior predictor to and independent of apo B-100
![Page 22: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/22.jpg)
NMR HDL-P better risk predictor than HDL-C
Framing. Offspring Study*†
PLAC-1*
VA-HIT*†
MESA*†
Women’s Health Study*†
NMR HDL-P better predictor of therapy response that HDL-C
PLAC-1*
VA-HIT*†
NMR HDL-P vs. HDL-C
* Independent of sex, age, smoking status and BP, and all lipid panel parameters† Superior predictor to and independent of apo B-100
![Page 23: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/23.jpg)
![Page 24: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/24.jpg)
Treatment Summary
Only BAS
Only Ω-3 FA
Only Fibrates/
pioglitazone
any?Niacin
any or or Ezetimibe
any or or Statins
Large
VLDL-P
HDL-PLDL
Size
Small
LDL-P
LDL-P
![Page 25: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/25.jpg)
![Page 26: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/26.jpg)
Patient Bradley
TC = 145LDL-C = 93 (15th)HDL-C = 39 (20th)TG = 66Non HDL-C = 106 (10th)
• 65 YO WM, 71” tall 198#, BP 110/70m, never smoker, neg FHx of premature atherosclerosis, Dx of BPH, Dyslipoproteinemia, Atrial fibrillation, ED
• Lipoprotein Therapy: Pravastatin 20 MG QD
LDL-P = 1560 (60th)HDL-P = 28.7 (40th)Small LDL-P = 1369LDL Particle Size = 19.8 Pattern B = 20.5-18.0Large HDL-P = 6.8 (50th)Large VLDL-P = 0.1
![Page 27: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/27.jpg)
Patient Bradley
TC = 123LDL-C = 68 (3rd)HDL-C = 42 (25th)TG = 63Non HDL-C = 81 (2nd)
LDL-P = 1045 (20th)HDL-P = 27.7 (38th)Small LDL-P = 722LDL Particle Size = 20.9 Pattern A = 23.0-20.6Large HDL-P = 9.0 (75th) Large VLDL-P = 0.2
• 65 YO WM, 71” tall 198#, BP 110/70m, never smoker, neg FHx of premature atherosclerosis, Dx of BPH, Dyslipoproteinemia, Atrial fibrillation, ED
• Changed from pravastatin to rosuvastatin 10 MG QD.
![Page 28: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/28.jpg)
Patient Gregory
TC = 199LDL-C = 132 (50th)HDL-C = 54 (75th)TG = 67Non HDL-C = 145 (40th)
• 43 YO WM, 68” tall 155#, BP 110/80m, never smoker, non-drinker, regular exercise,+ FHx of premature atherosclerosis, No medical diagnoses.
• Lipoprotein Therapy: None
LDL-P = 1147 (30th)HDL-P = 25.0 (18th)Small LDL-P = 517LDL Particle Size = 21.6 Pattern A = 23.0-20.6Large HDL-P = 9.3 (80th)Large VLDL-P = 0.7 (20th)
• CXR: Mild Aortic Calcification• Carotid U/S: minimal non-calcifying plaque L CCA and bilat ICA
![Page 29: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/29.jpg)
Patient Gregory
TC = 118LDL-C = 69 (< 2nd)HDL-C = 42 (28th)TG = 33Non HDL-C = 76 (< 2nd)
• 43 YO WM, 68” tall 155#, BP 110/80m, never smoker, non-drinker, regular exercise,+ FHx of premature atherosclerosis, No medical diagnoses.
• Lipoprotein Therapy: simvastatin 20 MG QD
LDL-P = 808 (3rd)HDL-P = 26.2 (21st)Small LDL-P = 508LDL Particle Size = 21.1 Pattern A = 23.0-20.6Large HDL-P = 8.3 (78th)Large VLDL-P = 0.0 (5th)
![Page 30: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/30.jpg)
Patient Gregory
TC = 152LDL-C = 97 (19th)HDL-C = 50 (65th)TG = 25Non HDL-C = 102 (10th)
• 43 YO WM, 68” tall 155#, BP 110/80m, never smoker, non-drinker, regular exercise,+ FHx of premature atherosclerosis, No medical diagnoses.
• Lipoprotein Therapy: lovastatin/ER niacin 1000/40 MG QD
LDL-P = 907 (7th)HDL-P = 31.0 (60th)Small LDL-P = 563LDL Particle Size = 21.1 Pattern A = 23.0-20.6Large HDL-P = 12.4 (95th)Large VLDL-P = 0.1 (10th)
• Carotid U/S: No demostrable plaque either carotid artery
![Page 31: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/31.jpg)
Patient Fancher
TC = 187LDL-C = 84 (4th)HDL-C = 55 (52th)TG = 242Non HDL-C = 132 (30th)
LDL-P = 763 (3rd)HDL-P = 40.6 (80th)Small LDL-P = 443LDL Particle Size = 21.1 Pattern A = 20.5-18.0Large HDL-P = 5.4 (60th)Large VLDL-P = 5.9
• 53 YO WF, 64” tall, 158#, BP 120/80, Never smoker, Dx IFG (FBS 110), menopause, s/p Radical Urinary Cystectomy and continent colon reservoir for Transitional Bladder CA
• Current Meds: None
• Lipoprotein therapy: None
![Page 32: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/32.jpg)
Patient Chew
TC = 192LDL-C = 73 (2nd)HDL-C = 58 (55th)TG = 303Non HDL-C = 134 (30th)
LDL-P = 1913 (85th)HDL-P = 39.7 (80th)Small LDL-P = 1404LDL Particle Size = 20.4 Pattern B = 20.5-18.0Large HDL-P = 12.3 (95th)Large VLDL-P = 13.7
• 46 YO WF, 67” tall, 202#, BP 120/76, no tobacco since 93, 16 pack-year hx previously, Dx of menopause, Dyslipoproteinemia, IFG, Hepatic steatosis
• Current Meds: levothyroxine 150 MCG QD, spironolactone 50 MG QD, CEE 0.625 QD, HCTZ 12.5 QD, escitalopram 20 MG QD, buproprion 150 MG QD
• Lipoprotein therapy: rosuvastatin 10 MG QD
![Page 33: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/33.jpg)
Patient Chew
TC = 146LDL-C = 62 (1st)HDL-C = 48 (18th)TG = 181Non HDL-C = 98 (7th)
LDL-P = 1434 (50th)HDL-P = 36.2 (70th)Small LDL-P = 1103LDL Particle Size = 20.45 Pattern B = 20.5-18.0Large HDL-P = 7.2 (60th)Large VLDL-P = 2.6
• 46 YO WF, 67” tall, 202#, BP 120/76, no tobacco since 93, 16 pack-year hx previously, Dx of menopause, Dyslipoproteinemia, impaired fasting glucose, Hepatic steatosis
• Current Meds: levothyroxine 150 MCG, spironolactone 50 MG QD, CEE 0.625 QD, HCTZ 12.5 QD, lexapro 20 MG QD, buproprion 150 MG QD
• Added Omega-3 Fatty Acid Ethyl Esters 4 G QD to rosuvastatin 10 MG QD
![Page 34: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/34.jpg)
Patient Jones
TC = 158LDL-C = 80 (5th)HDL-C = 62 (75)TG = 79Non HDL-C = 96 (5th)
LDL-P = 1459 (50th)Small LDL-P = 1067LDL Particle Size = 20.7 Pattern A = 23.0 - 20.6Large HDL-P = 6.8 (50th)Large VLDL-P = 0.1
• 60 YO BM, 72” tall, 194#, 150/70, never smoker, Dx HTN, Dyslipoproteinemia
• Current Meds: ramipril 10 MG QD, spironolactone/HCTZ 12.5/12.5 MG QD
• Lipoprotein Therapy: lovastatin/ER niacin 1000/40 MG QD
![Page 35: Dyslipoproteinemia and Atherosclerosis Daniel W. Stock MD Founding Diplomate, American Board of Clinical Lipidology Member, National Lipid Association.](https://reader035.fdocuments.net/reader035/viewer/2022062516/56649d9e5503460f94a881ff/html5/thumbnails/35.jpg)
Patient Jones
TC = 135LDL-C = 86 (10th)HDL-C = 63 (75th)TG = 62Non HDL-C = 72 (1st)
LDL-P = 953 (10th)Small LDL-P = 652LDL Particle Size = 20.9 Pattern A = 23.0 - 20.6Large HDL-P = 10.1 (90th)Large VLDL-P = 0.2
• 60 YO BM, 72” tall, 194#, 150-70, never smoker, Dx HTN, Dyslipoproteinemia
• Current Meds: Altace 10 MG QD, spironolactone/HCTZ 12.5/12.5 MG QD
• Changed to rosuvastatin 10 MG QD and ER niacin 1000 MG QD